Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway

Fig. 2

LncRNA RERE-AS1 enhances anti-tumor effect of ribociclib in BC cells. A Diagnostic value of 11 lncRNAs associated with ribociclib sensitivity, as determined by ROC analysis; B Differences in ribociclib IC50 values between patient groups with low- and high-expression of RERE-AS1; C Levels of RERE-AS1 expression in human BC cell lines; D Construction of MCF-7 and MDA-MB-231 cell lines with stable overexpression of RERE-AS1; E Variations in ribociclib IC50 values between control and overexpressed RERE-AS1 cells; F, G Clone formation and EdU experiments in control and RERE-AS1 overexpressing cells, under various concentrations of ribociclib treatment. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us